Teva Pharmaceutical Industries (TEVA) Consolidated Net Income (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Consolidated Net Income across 11 years of filings, most recently posting $370.0 million for Q1 2026.

• Quarterly Consolidated Net Income rose 68.18% year-over-year to $370.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 217.3% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.58% from the prior year.
• Consolidated Net Income declined to $370.0 million in Q1 2026, from $470.0 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $519.0 million in Q1 2024 and troughed at -$1.3 billion in Q4 2022.
• A 5-year average of -$140.6 million and a median of $64.0 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 1286.59% — and 2024, when it surged 305.14%.
• Tracing TEVA's Consolidated Net Income over 5 years: stood at -$1.3 billion in 2022, then surged by 134.93% to $466.0 million in 2023, then slumped by 159.01% to -$275.0 million in 2024, then soared by 270.91% to $470.0 million in 2025, then declined by 21.28% to $370.0 million in 2026.
• Business Quant data shows TEVA's Consolidated Net Income at $370.0 million in Q1 2026, $470.0 million in Q4 2025, and $432.0 million in Q3 2025.